
Now, a team from Russia has investigated the potential of this compound to be delivered to diseased target sites in the body using nanoscopic carriers known as liposomes. The team suggests that the liposomes can more efficiently deliver the putative drug compound to cancer cells than it simply being delivered by conventional chemotherapy methods (as a drug solution given either by mouth or intravenously).
Their tests revealed that the liposome preparations gave a prolonged release of the drug rather than it being processed quickly by the liver and excreted by the kidneys as happens with conventional drugs. Indeed, the drug-bearing liposomes showed a dose-dependent response in terms of cytotoxicity in the laboratory against B16 cells (experimental mouse melanoma cells).
“Liposomal sanguinarine may have advantages for in vivo anticancer therapy, due to its lower toxicity and ‘passive targeting’ as a result of enhanced permeability of tumour vessels,” the team reports in the International Journal of Nanotechnology.
Feldman, N.B., Kuryakov, V.N., Sedyakina, N.E., Gromovykh, T.I. and Lutsenko, S.V. (2018) ‘Preparation of liposomes containing benzophenanthridine alkaloid sanguinarine and evaluation of its cytotoxic activity’, Int. J. Nanotechnol., Vol. 15, Nos. 4/5, pp.280-287.
No comments:
Post a Comment